|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.115 CAD | +21.05% |
|
-4.17% | -36.11% |
| Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
Valeo Pharma Inc. reported earnings results for the full year ended October 31, 2023. For the full year, the company reported sales was CAD 53.91 million compared to CAD 27.75 million a year ago. Net loss was CAD 27.81 million compared to CAD 25.75 million a year ago.
Basic loss per share from continuing operations was CAD 0.32 compared to CAD 0.32 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -36.11% | 8.29M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
VALEO PHARMA INC. 
